The Role of Circulating Tumor DNA in Evaluating Minimal Residual Disease in Luminal Gastrointestinal Malignancies

Benjamin E. Ueberroth, Jeremy C. Jones, Tanios Bekaii-Saab

Research output: Contribution to journalArticlepeer-review

Abstract

The analysis of circulating tumor DNA (ctDNA) has multiple uses in oncology. In the past few years, studies with vary-ing designs, methods, and quality have emerged that show promise for the use of ctDNA as a tool to detect minimal residual disease (MRD) across luminal gastrointestinal malignancies. This review of the current literature looks at ctDNA in relation to detecting MRD, predicting patient prognosis, and assessing risk for recurrence.

Original languageEnglish (US)
Pages (from-to)444-455
Number of pages12
JournalClinical Advances in Hematology and Oncology
Volume20
Issue number7
StatePublished - Jul 2022

Keywords

  • Circulating tumor DNA
  • gastrointestinal cancer
  • MRD
  • prognosis
  • residual disease

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'The Role of Circulating Tumor DNA in Evaluating Minimal Residual Disease in Luminal Gastrointestinal Malignancies'. Together they form a unique fingerprint.

Cite this